您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2015, Vol. 53 ›› Issue (4): 12-15.doi: 10.6040/j.issn.1671-7554.0.2015.036

• 基础医学 • 上一篇    下一篇

紫杉醇协同肿瘤坏死因子相关凋亡诱导配体抑制胶质瘤细胞活性的探讨

邢德广1, 马二猛2, 王谋龙3, 孙中正1, 樊明德1, 臧贻征1, 王成伟1   

  1. 1. 山东大学第二医院神经外科, 山东 济南 250033;
    2. 中国医科大学附属第一医院神经外科, 辽宁 沈阳 110001;
    3. 山东能源淄博矿业集团中心医院神经外科, 山东 淄博 255120
  • 收稿日期:2015-01-12 修回日期:2015-04-02 出版日期:2015-04-10 发布日期:2015-04-10
  • 通讯作者: 王成伟.E-mail:wangchengwei@sdu.edu.cn E-mail:wangchengwei@sdu.edu.cn
  • 基金资助:
    山东省自然科学基金(2013ZRE27073);山东大学第二医院科研基金(S2014010011)

Experimental research on biological activities of glioma cells inhibited by TRAIL in combination with paclitaxel

XING Deguang1, MA Ermeng2, WANG Moulong3, SUN Zhongzheng1, FAN Mingde1, ZANG Yizheng1, WANG Chengwei1   

  1. 1. Department of Neurosurgery, The Second Hospital of Shandong University, Jinan 250033, Shandong, China;
    2. Department of Neurosurgery, The First Hospital of China Medical University, Shenyang 110001, Liaoning, China;
    3. Department of Neurosurgery, Central Hospital of Shandong Energy Zibo Mining Group Co., Ltd, Zibo 255120, Shandong, China
  • Received:2015-01-12 Revised:2015-04-02 Online:2015-04-10 Published:2015-04-10

PDF (PC)

150

摘要： 目的 探讨紫杉醇(PX)联合肿瘤坏死因子相关凋亡诱导配体(TRAIL)对胶质瘤U251细胞凋亡作用的影响及其可能机制.方法 分别采用改良MTT法和流式细胞术检测PX和TRAIL单独用药以及TRAIL/PX联合用药U251细胞后细胞增殖和凋亡的情况,采用Western bloting 法检测PX对U251细胞TRAIL受体DR4和DR5表达的影响.结果 TRAIL和PX单独用药对U251细胞增殖均具有抑制作用且呈浓度依赖性,TRAIL/PX联合作用对U251细胞生长抑制率和凋亡率均大于单独用药(P <0.05),TRAIL/PX联合用药与单独用药相比可显著上调DR4表达(P <0.05),DR5表达无明显变化.结论 PX可协同TRAIL上调DR4的表达,进而提高胶质瘤细胞对TRAIL的敏感性,抑制细胞增殖和诱导细胞凋亡.

关键词: 肾性骨病, 紫杉醇, 肿瘤坏死因子相关凋亡诱导配体, 胶质瘤, U251细胞, 凋亡, 甲状旁腺激素, 血液透析

Abstract: Objective To explore the effects of paclitaxel (PX) in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on glioma U251 cell apoptosis and its possible mechanism. Methods The proliferation and apoptosis of U251 cells treated by TRAIL/PX in combination or alone at different concentrations were detected with modified MTT and flow cytometry. Proteins of U251 cell TRAIL death receptor DR4 and DR5 were measured with Western blot assay. Results Both TRAIL and PX had inhibitory effect on U251 cell proliferation in a concentration-dependent manner, combined TRAIL/PX treatment had remarkably higher inhibitory effect on cell growth and apoptosis of U251 cells than either drug used lone (P <0.05). Furthermore, combined TRAIL/PX treatment showed a synergistic effect on U251 to upregulate the expression of DR4 (P <0.05), but had no effect on the expression of DR5. Conclusions PX can improve the sensitivity of glioma U251 cells to TRAIL by upregulation of DR4, and then inhibit glioma cell proliferation and induce apoptosis.

Key words: Glioma, U251 cells, Hematodialysis, Parathyroid hormone, Paclitaxel, TNF-related apoptosis-inducing ligand, Apoptosis, Renal osteopathy

中图分类号: 

  • R739.41
[1] Talibi SS, Aweid B, Aweid O. Prospective therapies for high-grade glial tumours: A literature review[J]. Ann Med Surg(Lond), 2014, 3(3): 55-59.
[2] Khan M, Bi Y, Qazi JI, et al. Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway[J]. Mol Med Rep, 2015, 11(1): 257-262.
[3] Ismail B, Fagnere C, Limami Y, et al. 2'-Hydroxy-4-methylsulfonylchalcone enhances TRAIL-induced apoptosis in prostate cancer cells[J]. Anticancer Drugs, 2015, 26(1): 74-84.
[4] Xu F, Wang F, Yang T, et al. Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells[J]. Cancer Cell Int, 2014, 14(1): 538.
[5] Hunter TB, Manimala NJ, Luddy KA, et al. Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF[J]. Anticancer Res, 2011, 31(10): 3193-3204.
[6] Qiu B, Sun X, Zhang D, et al. TRAIL and Paclitaxel synergize to kill U87 cells and U87-derived stem-like cells in vitro[J]. Int J Mol Sci, 2012, 13(7): 9142-9156.
[7] Wang F, Lin J, Xu R. The molecular mechanisms of TRAIL resistance in cancer cells: help in designing new drugs[J]. Curr Pharm Des, 2014, 20(42): 6714-6722.
[8] Gretney E, Takeda K, Smyth MJ. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway[J]. Int J Biochem Cell Biol, 2007, 39(2): 280-286.
[9] van Roosmalen IA, Quax WJ, Kruyt FA. Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function?[J]. Biochem Pharmacol, 2014, 91(4): 447-456.
[10] Holland PM. Death receptor agonist therapies for cancer, which is the right TRAIL?[J]. Cytokine Growth Factor Rev, 2014, 25(2): 185-193.
[11] Zhan C, Wei X, Qian J, et al. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo[J]. J Control Release, 2012, 160(3): 630-636.
[12] Yoshida T, Zhang Y, Rivera RL, et al. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells[J]. Mol Cancer Res, 2009, 7(11): 1835-1844.
[13] Tu LX, Wu YO, Zhang LJ. Experimental study on apoptosis of SGC-7901 cell induced by TRAIL combined with paclitaxel[J]. Chinese Journal of Immunology, 2012, 28(4): 308-311.
[14] Huang T, Li XH, Li XC, et al. Study on the apoptosis of osteosarcoma cell induced by combination of TRAIL and Paclitaxel[J]. China Journal of Modern Medicine, 2013, 23(2): 42-45.
[15] Tan QP, Liu Y, Qiu YZ, et al. Synergistic interactions of TRAIL and paclitaxel on the nasopharyngeal carcinoma cell lines in vitro[J]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2012, 26(7): 319-322.
[16] Sun X, Pang Z, Ye H, et al. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome[J]. Biomaterials, 2012, 33(3): 916-924.
[1] 张士宝 刘庆勇 阮喜云 陈杰 张建军 李宗武 杨广笑 王全颖. NT4-SAC-HA2-TAT融合基因表达载体的构建及鉴定[J]. 山东大学学报(医学版), 2209, 47(6): 15-19.
[2] 鹿向东 杨伟 徐广明 曲元明. 脑膜瘤中PPAR-γ的表达及曲格列酮对脑膜瘤培养细胞生长的影响[J]. 山东大学学报(医学版), 2209, 47(6): 65-.
[3] 王琳琳 孙美丽 孙玉萍 张楠 刘传勇. 中心体α-微管蛋白、γ-微管蛋白在脑胶质瘤中的表达及其与Survivin表达的相关性研究[J]. 山东大学学报(医学版), 2209, 47(6): 103-.
[4] 李刚,薛皓,邱伟,赵荣荣. 脑胶质瘤抑制性免疫微环境形成机制及研究进展[J]. 山东大学学报 (医学版), 2020, 1(8): 67-73.
[5] 吴强,何泽鲲,刘琚,崔晓萌,孙双,石伟. 基于机器学习的脑胶质瘤多模态影像分析[J]. 山东大学学报 (医学版), 2020, 1(8): 81-87.
[6] 陈安静,张训. 靶向小类泛素化修饰的胶质瘤治疗新策略[J]. 山东大学学报 (医学版), 2020, 1(8): 88-94.
[7] 江涛. 类脑智能在脑科学的前沿应用[J]. 山东大学学报 (医学版), 2020, 1(8): 10-13.
[8] 徐继禧,陈伟健. 髓内弥漫性中线胶质瘤伴H3 K27M突变1例[J]. 山东大学学报 (医学版), 2020, 1(7): 96-101.
[9] 董伟,邢乃栋,吕家驹,刘帅,孙亮,曹庆伟,董宇昊,刘钊,丁森泰. 靶向抑制有丝分裂驱动蛋白治疗多西紫杉醇耐药前列腺癌的体外疗效[J]. 山东大学学报（医学版）, 2017, 55(9): 23-30.
[10] 张亮,徐敏,庄向华,娄福臣,娄能俊,吕丽,郭文娟,郑凤杰,陈诗鸿. 内质网应激与凋亡在糖尿病周围神经病变中的表达变化[J]. 山东大学学报（医学版）, 2017, 55(8): 13-17.
[11] 李睿,马伟红,任满意,赵萌萌,姜珊,巨媛媛,郭颖,孙昭辉,隋树建. TWEAK与原发性高血压患者心脏重塑的相关性[J]. 山东大学学报（医学版）, 2017, 55(5): 49-55.
[12] 郭贺贺,孙志强,刘艳娟,刘奕晨,李广,郑方. 去甲斑蝥素对骨髓瘤U266细胞Notch信号通路表达的影响[J]. 山东大学学报（医学版）, 2017, 55(3): 32-37.
[13] 涂云华,陈利远,王喜,周英,康颖倩,薛月萃,荣冬芸,叶振源,曹煜. 芳姜黄酮衍生物对WM35细胞增殖及凋亡的影响[J]. 山东大学学报（医学版）, 2017, 55(2): 68-73.
[14] 王超超,田海龙,姜慧峰,郭文强,王志刚. 荧光素钠“黄荧光”导航辅助高级别胶质瘤手术治疗的临床意义[J]. 山东大学学报（医学版）, 2017, 55(11): 32-37.
[15] 巩璐伟,周丽珍,苏国海. 培哚普利通过调节Akt-FoxO1通路保护糖尿病性心肌病大鼠心功能损伤[J]. 山东大学学报（医学版）, 2017, 55(10): 65-70.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发